arrow
D

David Groff

children's hospital of philadelphia
H指数:16
被引数:1,384

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity

PLK4抑制剂RP-1664通过双重敏感性机制在神经母细胞瘤临床前模型中显示出显著疗效

2026-06-130
OAAI
Target antigen–displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma

靶向抗原展示的外泌体在神经母细胞瘤的细胞和鼠模型中增强了CAR T细胞的疗效

2025-11-190
OAAI
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

具有吡咯并苯并二氮杂payload的人源化间变性淋巴瘤激酶 (ALK) 定向抗体-药物偶联物在表达ALK的癌症中具有功效

2025-08-150
OA
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
2024-07-311
OAAI
In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): An update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program
2024-04-051
PRE
Targeting of intracellular oncoproteins with peptide-centric CARs

以肽为中心的car靶向细胞内癌蛋白

Nature
IF48.5
2023-11-080
OAAI
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

高危神经母细胞瘤astatine-211-parthanatine的临床前研究

2022-11-1710
OAAI
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

[211At] 间-苄基胍 ([211At]MABG) 作为神经母细胞瘤的 α粒子放射性药物疗法的临床前开发

2022-07-217
OAAI
LIM domain-binding 1 maintains the terminally differentiated state of pancreatic β cells
2016-12-1263
OA